The BET inhibitor suppresses the outgrowth of ovarian cancer cells treated with cisplatin in vitro and in vivo while also improving the survival of ovarian cancer bearing mice treated with cisplatin [148]. This evidence concerns the gene DNER and ovarian carcinoma.